FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:58-59 July 7, 1994 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: Dipyridamole, a widely used vasodilatory drug, enhances renal tubular reabsorption of phosphate by decreasing adenosine uptake by tubular cells.¹ In rats, dipyridamole prevents phosphate excretion induced by cyclic AMP and decreases the phosphaturic effect of parathyroid hormone.¹ This demonstrates that adenosine, a local product of the degradation of nephrogenous cyclic AMP, is associated with phosphaturia. We sought to determine whether dipyridamole might decrease urinary phosphate excretion in humans.

We evaluated the short-term effect of dipyridamole in 48 people (22 men and 26 women) with a mean age of 52 years (range, 26 to 74). Twelve were normal . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.